|
Title
|
Published
|
Price
|
By
MP Advisors
Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening of glycemic control and ~half of them end up with daily...
|
February
2013
|
$
1000
|
By
MP Advisors
The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of ...
|
February
2013
|
$
1000
|
By
MP Advisors
¥200b worth of biologic products is going off patent by 2015 and this value exceeds ~ ¥500b if we include products that will see their patent expiries by 2021 in Japan. There are a number of reasons to believe that follow-on-biologic...
|
January
2013
|
$
1000
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for antitoxins, antivenoms, immune globulins, and therapeutic immune serums for therapeutic use and passive immunization excluding diagnostics across the regions of Greater China, including prov
|
January
2013
|
$
495
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for diagnostic, therapeutic, and patient monitoring equipment and other electromedical equipment excluding ionizing radiation equipment across the regions of Greater China, including provinces,
|
January
2013
|
$
495
|
By
IMARC Group
Report SummaryAdvancements in antibody technology has revolutionized both the diagnostic and therapeutic sciences. As of today, monoclonal antibodies can be produced virtually against any antigen and they have transfor...
|
January
2012
|
$
1000
|
By
Biopharm Reports
This report provides a comprehensive review of 27 candidate therapeutic antibodies that are being evaluated for the treatment of lung cancer; cov...
|
October
2011
|
$
1200
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of ...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication ...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of deve...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of develo...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of ...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication a...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of develo...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and ...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of developme...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and st...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of develop...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication a...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication an...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage ...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication a...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of de...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and s...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication an...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of de...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of dev...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and st...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of de...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company pr...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stag...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of developme...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage o...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indicati...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of devel...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of de...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of de...
|
March
2011
|
$
350
|